Bayer Aktiengesellschaft

Bayer Pharma Aktiengesellschaft

Bayer Intellectual Property Gmbh

Bayer Schering Pharma Ag

Bayer Healthcare Aktiengesellschaft

Peter Serno

Karl-Heinz Schlemmer

Elisabeth Perzborn

Thomas Schenke

Mazen Es-Sayed

Erwin Bischoff

Klaus Dembowsky

Helmut Haning

Marc Nowakowski

Jörg Keldenich

Andreas Ohm

Maria Niewöhner, Legal Representative

Alfons Grunenberg

Britta Olenik

Heiko Schirmer

Donald Bierer

Ulrich Niew&ouml;hner

J&ouml;rg Keldenich

Ulrike Fuhrmann

Kai Lovis

Peter Kurka

Rainer Bellinghausen

Philipp Rubenbauer

Bernhard Lindenthal

Ulrich Niewöhner

Danja Grossbach

Jan-Olav Henck

Julia Küsel

Anke Stroyer

Tia Jacobs

Carmen Lobback

Stanislav Kazda

Bernd Buchmann

Bernd Klinksiek

Andrea Rotgeri

Anne Mengel

Venkata-Rangarao Kanikanti

Nico Bräuer

Antonius Ter Laak

Klaus Schlossmann

Gunther Penners

Ulrike Röhn

Yutaka Hayauchi

Robert Frank Lammens

Norbert Pollinger

Stefan Kettelhoit

Alfred Zembrod

Hans-Martin Siefert

Matthias Herboth

Hans Friedrich Mahler

Dieter Beermann

Wolfram Hofmann

Eimer Vollers

Richard-Josef Bauer

Wolfgang Barth

Dieter Zimmer

Kerstin Pauli

Roland Heinig

Elmer Vollers

Stefanie Lindemann

Katrin Waellnitz

Elmer Volters

The present invention relates to orally administrable modified-release pharmaceutical dosage forms comprising sodium (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoate and to processes for preparing the dosage forms and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiac, renal and pulmonary disorders, disorders of the central nervous system, fibrotic and inflammatory disorders and metabolic disorders.

Orally administrable modified-release pharmaceutical dosage form

The invention relates to a pharmaceutical composition for non-hormonal, on-demand contraception and to processes for preparing this pharmaceutical composition. The latter comprises 2H-indazole as novel EP2 receptor antagonists in combination with COX inhibitors. The invention furthermore provides a method for non-hormonal female-controlled on-demand contraception where a pharmaceutical composition comprising EP2 receptor antagonists in combination with COX inhibitors is taken on demand prior to expected sexual intercourse.

Pharmaceutical composition and the use thereof, and application regime of said pharmaceutical composition for on-demand contraception

The invention relates to a method of hormonal female controlled 'on demand' contraception, in which a pharmaceutical preparation comprising a COX inhibitor and levonorgestrel is taken on demand prior to expected sexual intercourse. Further subjects of the invention relate to pharmaceutical compositions and application regimes for 'on demand' contraception.

Use and application regimen of a pharmaceutical composition containing levonorgestrel and a COX inhibitor for on-demand contraception

The invention relates to a method for producing medicaments that contain vardenafil hydrochloride, essentially as trihydrate in solid form, and to medicaments that can be obtained according to this method.

Medicaments containing vardenafil hydrochloride trihydrate

The present application relates to novel drug formulations of vardenafil which dissolve rapidly in the mouth and lead to increased bioavailability and to a plateau-like plasma concentration profile, and to processes for their preparation.

Pharmaceutical forms with improved pharmacokinetic properties

The 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of cardiovascular and cerebrovascular disorders and/or disorders of the urogenital system, in particular for the treatment of erectile dysfunction.

2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors

The application claims a compound of the formula  The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of erectile dysfunction.

The application claims a method for treating hypertension by administering an effective amount of a compound of the formula (I) wherein the variable groups are as defined in the specification and claims. These 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of cardiovascular and cerebrovascular disorders and/or disorders of the urogenital system, in particular for the treatment of erectile dysfunction.

2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors, for treatment of hypertension

The present invention relates to imidazotriazinone-containing compositions for nasal administration which, besides the cGMP PDE inhibitor, contain a small amount of a local anaesthetic.

Imidazotriazinone-containing compositions for nasal administration

2-phenyl substituted imidatriazinones as phosphodiesterase inhibitors

The invention relates to a special process for the preparation of stable, solid medicament formulations of high bioavailability and with controlled release comprising sparingly soluble active compounds and polymeric auxiliaries, and to the formulations thus prepared.

Process for the preparation of medicament formulations with controlled

Growing community of inventors

Bergisch Gladbach, Germany

Peter Serno